The studies that exist so far to the current pandemic of COVID-19 produced by the SARS-CoV-2 coronavirus, report neuropsychiatric symptoms only as part of the manifestation of the disease in its terminal phase. However, even if the infection is mild, moderate or severe, there are neuropsychiatric symptoms since the beginning of the disease. Already in the advanced stages of the severe acute respiratory syndrome (SARS), different neuropsychiatric manifestations have been reported as a form of clinical expression of the course of infection, which could be a direct output of cerebral hypoxia due to respiratory failure, viral brain tissue infection or encephalitis, immune system reaction or cytokine storm or a combination of all these factors. Neuropsychiatric manifestations include anxiety symptoms, panic attacks, depression, mental confusion, acute confusional syndrome, psychomotor excitement, psychosis, and even suicidal tendencies

The presence of stroke is being observed in young adults (under 50 years of age) without cardiovascular risk factors suffering from COVID-19. It is speculated whether there is really a significant increase, as few cases have yet been described, or whether the infection actually favors their development. Cerebrovascular events were more common in older patients with stroke risk factors such as hypertension and diabetes mellitus, and those who had elevated fibrin D-dimers. Multiple cases reports and series about cerebrovascular disease in COVID-19 has been informed. The mechanism that causes cerebral ischemia in COVID-19 remains undiscovered, however, progressively there is increasing evidence of a hypercoagulable state that could be or contribute to the cause of cerebrovascular disease. We review the current literature about cerebrovascular disease, both epidemiology and etiology. More studies are needed to understand COVID-19 neuropathogenesis and the presence of stroke in this patient.

The worldwide population prevalence of autism is about 1%. The current panorama that we are experiencing with the COVID-19 pandemic, makes it difficult for many people to understand and assimilate everything what is happening. In persons with autism, this difficulty can become extreme, both in children and adults. However, there are some recommendations to help process and assimilate this situation and like this avoid or reduce complications in this population. This recommendations are simple, but they are difficult to perform. However, they can help keep the loved ones and their family members more bearable. Only by knowing its characteristics and applying a few recommendations or guidelines, caregivers and the affected persons will be able to lead a more enjoyable life.

Abstract A new human coronaviruses (SARS-CoV-2) are the cause of currently severe acute respiratory syndrome (SARS), as occurred in the previous epidemic caused by SARS-CoV-1. Perampanel is a drug currently used in epilepsy, with an innovative mechanism of action, through receptors [2-amino-3- (3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA) that modulates the flow of glutamate. It has been reported the utility of another drugs used in neurodegenerative disorders such a memantine. It works through the N-methyl-D-aspartate receptor (NMDA) and regulates the transporting of glutamate. Both are receptor antagonists. Memantine has seen to reduce the symptoms and replication viral in animal models infected with HCoV. We propose that perampanel works in a similar way and may have therapeutic and neuroprotective effects in COVID-19 infection. New studies on it should be started.